Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch

Compass Pathways (CMPS) has completed its FDA application for psilocybin therapy (COMP360) and is preparing for launch. The company expects revenue to begin late Q2 or Q3 2024, pending approval and rescheduling. It is also planning reimbursement support and patient assistance programs. Compass is confident in its commercial positioning despite competition. The company is also conducting trials for post-traumatic stress disorder.

Original reporting
Published Nov 12, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch — source image
Decision brief

The 30-second read

$CMPSBullishMed
01

Why it matters

The filing is a material regulatory event that could drive the stock higher if the FDA grants approval, but the timeline for revenue is delayed until late Q2/Q3 of next year, adding uncertainty.

02

Market read

First disclosure of the FDA filing creates a fresh catalyst for CMPS and may influence the psychedelic‑therapy sector.

03

What to watch

Potential competition from Usona Institute's psilocybin program and the need for state rescheduling could delay commercial rollout.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Compass Pathways (NASDAQ:CMPS) announced completion of its FDA application for COMP360, a synthetic psilocybin therapy targeting treatment‑resistant depression, and outlined launch and reimbursement plans.

Company-level read

Ticker impact

$CMPSBullishHigh confidence
Context

Compass Pathways filed its FDA application for the psilocybin therapy COMP360, marking the first public disclosure of the submission.

Expected impact

possible upward pressure as investors price in the chance of approval, tempered by uncertainty around scheduling and reimbursement.

Evidence & confidence

Regulatory filings for novel psychedelics are rare and can move biotech stocks sharply; the market will likely react positively to any progress toward approval.

Market effects

May boost sentiment for the broader psychedelic‑therapy sector and other mental‑health biotech firms.

Primarily U.S. biotech market; limited immediate effect on broader indices.

Limited to investors tracking emerging‑therapy biotech stocks worldwide.

Counterpoint

Approval risk remains high; regulatory hurdles and reimbursement uncertainty could outweigh upside.

Key entities

  • Compass Pathways

    Biotech firm developing psilocybin‑based therapies.

  • FDA

    U.S. Food and Drug Administration reviewing the COMP360 application.

Related articles

$CMPSHighAI 9/10

Compass Pathways stock gains on FDA filing for depression drug

Compass Pathways (CMPS) shares rose 4.5% after submitting a New Drug Application to the FDA for its psilocybin-based depression treatment, COMP360. The submission is backed by positive Phase 3 trial data. The company expects a potential launch in early 2027, pending FDA approval. Jefferies reiterated a Buy rating and $18.00 price target, citing high confidence in FDA approval.

$CMPSMedAI 8/10

Compass Pathfinder Limited: Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

Compass Pathways (CMPS) submitted a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin to treat treatment-resistant depression (TRD). The submission is backed by data from Phase 3 trials and a Phase 2b study involving over 1,000 participants. The company aims for a potential launch in the first half of 2027, pending FDA approval.

$CMPSHigh

Oppenheimer reiterates Compass Pathways stock rating on NDA filing

Oppenheimer maintained an Outperform rating and $20 price target for Compass Pathways (CMPS) after its Q3 update. The company expects to file an NDA for COMP360 within two weeks, aiming for a 2027 launch. CMPS reported $56M in operating expenses, $444M in cash, and a Q3 loss of $0.31 per share, beating estimates. Analysts from TD Cowen, BTIG, and Stifel also reiterated Buy ratings with higher price targets, citing strong execution and trial results.